AC Immune (NASDAQ:ACIU) Shares Down 2.7% – What’s Next?

Shares of AC Immune (NASDAQ:ACIU) fell 2.7% during trading on Monday . The company traded as low as $2.18 and last traded at $2.19. 296,576 shares traded hands during trading, an increase of 10% from the average session volume of 270,272 shares. The stock had previously closed at $2.25.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ACIU. Jefferies Financial Group reissued a “buy” rating and set a $7.00 price target on shares of AC Immune in a research note on Friday, March 13th. Wall Street Zen raised AC Immune from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of AC Immune in a research note on Monday, May 4th. Finally, Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.50.

AC Immune Stock Performance

The stock has a 50 day moving average of $2.84 and a 200 day moving average of $3.00. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $215.75 million, a price-to-earnings ratio of -2.59 and a beta of 1.59.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%. As a group, analysts predict that AC Immune will post -0.84 EPS for the current year.

Insider Activity at AC Immune

In related news, CEO Andrea Pfeifer sold 10,000 shares of AC Immune stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $2.79, for a total value of $27,900.00. Following the transaction, the chief executive officer directly owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership increased its holdings in AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. EFG International AG bought a new stake in AC Immune in the fourth quarter worth approximately $41,000. Marshall Wace LLP bought a new stake in AC Immune in the fourth quarter worth approximately $586,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after acquiring an additional 5,920 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.